- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00779714
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC (ChemoSensMM)
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma
This phase III trial is aimed to investigate the efficacy of an individualized, sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC.
Two question are aimed to be answered by this study:
- Is the individual chemosensitivity index (BICSI) a prognostic / predictive biomarker for chemotherapy ?
- Is an individualized, sensitivity-directed combination chemotherapy superior to the standard regimen DTIC in terms of survival and response ?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Melanoma is a cutaneous neoplasm known for its high aggressiveness, its early dissemination of metastases, and its poor prognosis once metastasized. Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma, with reported response rates of about 10%. This poor outcome is assumed to be due to a high chemoresistance intrinsic to melanoma cells. However, other therapeutic options like polychemotherapy, biochemotherapy, immunotherapy as well as targeted agents did not yet prove to be superior to DTIC in multicenter randomized studies.
Therefore, chemotherapy still is considered as the main therapeutic option in advanced metastatic melanoma, and a number of non-standard chemotherapeutics have been tested in small pilot studies to improve treatment efficacy. Even though complete remissions of metastatic lesions could only be observed in a few patients, these observations indicate a subgroup of patients exhibiting high sensitivity to certain anticancer drugs. An in vitro ATP-based chemosensitivity assay has been shown to differentiate between chemosensitive and chemoresistant melanoma patients. A phase-II-study testing this assay in 53 metastatic melanoma patients followed by a sensitivity-directed individualized chemotherapy demonstrated, that the chemosensitivity profile of an individual patient, reflected by the best individual chemosensitivity index (BICSI), correlated with therapy outcome in terms of therapy response and patient overall survival (Ugurel S: Clin Cancer Res 2006). Interestingly, a surprisingly high proportion of about 2/5 of the investigated patient cohort were classified as chemosensitive, the remaining 3/5 were classified as chemoresistant. Objective response was 36.4% in chemosensitive patients compared to 16.1% in chemoresistant patients (p=0.114); progression arrest (CR+PR+SD) was 59.1% versus 22.6% (p=0.01). Chemosensitive patients showed an increased overall survival of 14.6 months compared to 7.4 months in chemoresistant patients (p=0.041).
These encouraging results prompted the initiation of this randomized phase-III-trial investigating an individualized sensitivity-directed combination chemotherapy compared to the current standard treatment DTIC, as first-line treatment in metastatic melanoma. The therapeutics for chemosensitivity testing and treatment of patients were chosen considering the results of the phase-II-trial (paclitaxel+cisplatinum, treosulfan+cytarabine).
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Selma Ugurel, Prof. (MD)
- Phone Number: 26118 0049931201
- Email: Ugurel_S@klinik.uni-wuerzburg.de
Study Locations
-
-
-
Aachen, Germany, 52074
- Recruiting
- Dept of Dermatology, University of Aachen
-
Principal Investigator:
- Hans F Merk, Prof. (MD)
-
Berlin, Germany, 10117
- Recruiting
- Dept of Dermatology, University of Berlin Charite
-
Principal Investigator:
- Uwe Trefzer, PD (MD)
-
Bochum, Germany, 44791
- Recruiting
- Dept of Dermatology, University of Bochum
-
Principal Investigator:
- Norbert Brockmeyer, Prof. (MD)
-
Bonn, Germany, 53111
- Recruiting
- Medizinisches Zentrum Bonn Friedensplatz
-
Principal Investigator:
- Uwe Reinhold, Prof. (MD)
-
Essen, Germany, 45147
- Recruiting
- Dept of Dermatology, University of Essen
-
Principal Investigator:
- Dirk Schadendorf, Prof. (MD)
-
Frankfurt / Main, Germany, 60590
- Recruiting
- Dept of Dermatology, University of Frankfurt
-
Principal Investigator:
- Roland Kaufmann, Prof. (MD)
-
Frankfurt/Oder, Germany, 15236
- Recruiting
- Dermatology, Klinikum Frankfurt/Oder
-
Principal Investigator:
- Anett Milling, Dr. (MD)
-
Hannover, Germany, 30449
- Recruiting
- Dept of Dermatology, University of Hannover
-
Principal Investigator:
- Ralf Gutzmer, PD (MD)
-
Homburg/Saar, Germany, 66421
- Recruiting
- Dept of Dermatology, Saarland University
-
Principal Investigator:
- Knuth Rass, Dr. (MD)
-
Jena, Germany, 07740
- Recruiting
- Dept of Dermatology, University of Jena
-
Principal Investigator:
- Martin Kaatz, Dr. (MD)
-
Kiel, Germany, 24105
- Recruiting
- Dept of Dermatology, University of Schleswig-Holstein Campus Kiel
-
Principal Investigator:
- Axel Hauschild, Prof. (MD)
-
Ludwigshafen, Germany, 67063
- Recruiting
- Dermatology, Klinikum Ludwishafen
-
Principal Investigator:
- Edgar Dippel, Prof. (MD)
-
Luebeck, Germany, 23538
- Recruiting
- Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck
-
Principal Investigator:
- Patrick Terheyden, Dr. (MD)
-
Magdeburg, Germany, 39120
- Recruiting
- Dept of Dermatology, Univeristy of Magdeburg
-
Principal Investigator:
- Martin Leverkus, Prof. (MD)
-
Mainz, Germany, 55131
- Recruiting
- Dept of Dermatology, University of Mainz
-
Principal Investigator:
- Carmen Loquai, Dr. (MD)
-
Mannheim, Germany, 68167
- Recruiting
- Dept of Dermatology, University of Mannheim
-
Principal Investigator:
- Jessica Hassel, Dr. (MD)
-
Marburg, Germany, 35033
- Recruiting
- Dept of Dermatology, University of Marburg
-
Principal Investigator:
- Michael Hertl, Prof. (MD)
-
Muenchen, Germany, 80337
- Recruiting
- Dept of Dermatology, University of Muenchen
-
Principal Investigator:
- Carola Berking, Prof. (MD)
-
Muenster, Germany, 48149
- Recruiting
- Dept of Dermatology, University of Muenster
-
Principal Investigator:
- Cord Sunderkoetter, Prof. (MD)
-
Muenster, Germany, 48157
- Recruiting
- Dept of Medical Oncology, Fachklinik Hornheide
-
Principal Investigator:
- Michael Fluck, Dr. (MD)
-
Quedlinburg, Germany, 06484
- Recruiting
- Dermatology, Klinikum Dorothea Christiane Erxleben
-
Principal Investigator:
- Jens Ulrich, PD (MD)
-
Tuebingen, Germany, 72086
- Recruiting
- Dept of Dermatology, University of Tuebingen
-
Principal Investigator:
- Claus Garbe, Prof. (MD)
-
Wuerzburg, Germany, 97080
- Recruiting
- Dept of Dermatology, University of Wuerzburg
-
Principal Investigator:
- Selma Ugurel, Prof. (MD)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed melanoma of the skin, mucosa, or unknown primary, diagnosed with surgically unresectable distant metastases (stage IV according to AJCC).
- At least one measurable target lesion according to RECIST, assessed by CT or MRI (tumor assessment by X-ray or ultrasonography only is not allowed).
- Access to a biopsy of ~1 cm3 from at least one metastatic lesion for in vitro chemosensitivity testing. Cell suspensions from malignant effusions are also eligible.
- No prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one prior regimen of immunotherapy or targeted therapy in stage IV allowed).
- No evidence of brain/CNS metastases. Former history of brain/CNS metastases, which have been treated successfully, and are no longer visible in CT/MRI is allowed.
- Last complete tumor assessment (CT or MRI of thorax, abdomen and brain) not older than 14 days prior to registration, and not older than 5 weeks prior to onset of study treatment.
- ECOG/WHO performance index of 0 or 1.
- Patients must have stopped any kind of previous antineoplastic therapy for at least 2 weeks prior to registration, and at least 4 weeks prior to treatment onset.
- Patients must not have concurrent or recent malignancies except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin. Patients with previous malignancies, which have been treated with a subsequent disease-free interval of at least 5 years, are eligible.
- Patient age ≥ 18 years.
Adequate hematological, renal and liver function as defined by the following laboratory values performed within 14 days prior to randomisation:
- absolute neutrophil count (ANC) ≥ 1.5 x 109/l
- platelet count ≥ 100 x 109/l
- hemoglobin ≥ 9 g/dl
- urea and serum creatinine ≤ 2 times upper normal limit (UNL)
- total and direct serum bilirubin ≤ 2 times UNL
- GOT or GPT ≤ 2.5 times UNL; ≤ 5 times UNL is allowed in case of liver metastasis
- alkaline phosphatase < 2.5 times UNL
- Female patients should not be pregnant or nursing. Women of childbearing potential should be using a highly effective method of birth control (e.g. implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner). For subjects using a hormonal contraceptive method, information regarding the product under evaluation and its potential effect on the contraceptive should be addressed.
- Male patients should use an effective method of contraception.
- Before registration, written informed consent must be given according to GCP guidelines and national/local regulations. Patients must be willing and giving informed consent to participation in the trial.
Exclusion Criteria:
- All metastatic lesions are surgically resectable.
- Prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one prior regimen of immunotherapy or targeted therapy in stage IV allowed).
- Primary melanoma of the uvea / choroidea.
- Evidence of brain/CNS metastases. Former history of brain/CNS metastases, which have been treated successfully, and are no longer visible in CT/MRI is allowed.
- ECOG/WHO performance index of 2 or higher
- Concurrent or recent malignancies except for surgically cured carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin. Patients with previous malignancies, which have been treated with a subsequent disease-free interval of at least 5 years, are eligible.
- Any severe or uncontrolled hematological, renal or liver dysfunction as defined by the laboratory values given in Inclusion Criteria.
- Any clinically uncontrolled infectious disease including HIV positivity or AIDS-related illness.
- Any female patients who are pregnant or nursing.
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration for the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A (individualized combined chemotherapy)
|
paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
Other Names:
treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
Other Names:
|
Active Comparator: B (DTIC monochemotherapy)
|
1000 mg/m2, d1 every 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-specific overall survival
Time Frame: 4 years
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Objective response
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Selma Ugurel, Prof. (MD), Dept of Dermatology, University of Wuerzburg
Publications and helpful links
General Publications
- Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006 Sep 15;12(18):5454-63. doi: 10.1158/1078-0432.CCR-05-2763.
- Ugurel S, Tilgen W, Reinhold U. Chemosensitivity testing in malignant melanoma. Recent Results Cancer Res. 2003;161:81-92. doi: 10.1007/978-3-642-19022-3_8.
- Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs. 1999 Jun;10(5):437-44. doi: 10.1097/00001813-199906000-00002.
- Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995 Nov 15;55(22):5276-82.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Cisplatin
- Cytarabine
- Dacarbazine
- Treosulfan
Other Study ID Numbers
- 101.321-13/07
- EudraCT Nr. 2008-001686-28
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
Clinical Trials on paclitaxel + cisplatin
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Recruiting
-
Taipei Veterans General Hospital, TaiwanCompletedNon-small-cell Lung CancerTaiwan
-
Peking UniversityNot yet recruitingThoracic Esophageal Squamous Cell CarcinomaChina
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
Qilu Hospital of Shandong UniversityWithdrawn
-
Henan Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingResectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Esophageal Squamous Cell CarcinomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell CarcinomaChina
-
Haruhiko FukudaMinistry of Health, Labour and Welfare, JapanCompletedUterine Cervical NeoplasmsJapan